Computer Guided Microwave Liver Ablation
Recruiting now · Not applicable
Conditions studied: Hepatocellular Carcinoma (HCC)
In brief
The goal of this clinical trial is to learn if the intraoperative use of a computer guidance software can improve the success of liver tumor ablation in adults. The employed software calculates and displays a simulation of the ablation such that the physician can visualize what portion of the target tumor has, and has not been treated at any point during the procedure. The main questions it aims to answer are: 1) Does the use of the computer guidance software reduce the number of times a tumor is incompletely treated. 2) Does the use of the computer guidance software reduce the rate of local tumor recurrence at 2 year follow-up? 3) Was there an increase or a decrease in medical problems for participants after a procedure where the guidance software was used? Researchers will compare liver tumor treatment using the computer guidance software with an historic control to see if the addition of the guidance software improved the outcomes after an ablation. Participants will: Undergo CT-guided microwave ablation treatment of a liver tumor using computer-assisted simulation. Visit the clinic at one month and then every 3 months for blood tests and a contrast-enhanced CT or MRI imaging study (as per standard of care)
Key facts
- Study ID
- NCT07226869
- Run by
- NE Scientific INC
- People needed
- 84
- Starts
- 2026-05-08
- Expected to finish
- 2030-02-28
- Last updated by the study team
- 2026-05-11
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years, with life expectancy of at least 1 year
- Diagnosis of hepatocellular carcinoma (HCC) confirmed by:
- LI-RADS 5 imaging features or
- Histopathology
- Cirrhosis with AFP > 400
- Localized disease without macrovascular invasion or extrahepatic metastasis, eligible for curative-intent percutaneous thermal ablation, defined as:
- o Up to 5 lesions with at least one lesion, 2 -5 cm, and no lesion >5 cm diameter
- Tumor location deemed technically feasible for percutaneous ablation by the treating interventional radiologist
- ECOG Performance Status 0-2
- Adequate coagulation status, defined as:
- Platelets ≥ 50,000/μL
- INR ≤ 1.8 (or correctable)
- Ability to undergo contrast-enhanced CT or MRI
- Willingness and ability to provide informed consent
You may not qualify if…
- Prior local therapy to the target lesion (ablation, TACE, SBRT, or resection) or to a lesion within 1 cm of the target lesion
- More than 5 hepatic lesions, or any lesion ineligible for technically complete ablation
- uncontrolled hepatic decompensation, including:
- o Persistent encephalopathy
- Uncorrectable coagulopathy or contraindication to percutaneous liver intervention
- Contraindication to contrast-enhanced imaging (e.g., severe CKD without dialysis, contrast allergy not correctable with premedication)
- Active systemic infection
- Pregnancy
- Inability to comply with follow-up imaging schedule
Where it is running
- Dartmouth HItchcock Medical Center — Lebanon, New Hampshire, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.